Autologous cancer stem cell therapy - Cellonis Biotechnologies

Drug Profile

Autologous cancer stem cell therapy - Cellonis Biotechnologies

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cellonis Biotechnologies
  • Class Antineoplastics; Cardiovascular therapies; Stem cell therapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Glioma

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Glioma(Recurrent) in China (Parenteral)
  • 30 Nov 2009 Phase-I clinical trials in Glioma in China (Parenteral)
  • 31 Mar 2009 Preclinical trials in Glioma in China (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top